Access to antifungal medicines in resource-poor countries - Authors' reply

The Lancet Infectious Diseases

Volumn 14, Issue 5, 2014, Pages 371-

  Loyse, Angela ^a   Thangaraj, Harry ^a   Govender, Nelesh P ^b   Harrison, Thomas ^a   Bicanic, Tihana ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MENINGITIS, CRYPTOCOCCAL;

EID: 84898981895     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70068-4     Document Type: Letter

References (4)

1. Jadhav MP, Bamba A, Shinde VM, et al. Liposomal amphotericin B (Fungisome™) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: a multicentric, randomised controlled trial. J Postgrad Med 2010, 56:71-75.
2. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children WHO, (accessed April 1, 2014). http://www.who.int/hiv/pub/cryptococcal_disease2011/en/index.html.
3. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010, 50:291-322.
4. Loyse A, Thangaraj H, Easterbrook P, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis 2013, 13:629-637.